Last updated: August 17, 2026
| Table 1. Top 100 Drugs by Sales | ||
| Rank | Drug (Brand Name) | Sales Through March 2014 |
| 1 | Abilify | $6,885,243,368 |
| 2 | Nexium | $6,271,376,299 |
| 3 | Humira | $5,936,288,498 |
| 4 | Crestor | $5,502,148,010 |
| 5 | Advair Diskus | $5,112,576,549 |
| 6 | Enbrel | $4,896,267,318 |
| 7 | Remicade | $4,235,535,358 |
| 8 | Cymbalta | $4,095,537,942 |
| 9 | Copaxone | $3,679,837,035 |
| 10 | Neulasta | $3,634,919,067 |
| 11 | Lantus Solostar | $3,375,632,862 |
| 12 | Rituxan | $3,320,475,967 |
| 13 | Spiriva Handihaler | $3,140,602,715 |
| 14 | Januvia | $2,975,320,499 |
| 15 | Atripla | $2,894,627,347 |
| 16 | Lantus | $2,796,784,267 |
| 17 | Avastin | $2,742,284,655 |
| 18 | Lyrica | $2,611,451,728 |
| 19 | Oxycontin | $2,528,601,587 |
| 20 | Epogen | $2,346,224,521 |
| 21 | Celebrex | $2,342,549,444 |
| 22 | Truvada | $2,307,970,304 |
| 23 | Diovan | $2,190,542,692 |
| 24 | Gleevec | $1,995,042,989 |
| 25 | Herceptin | $1,971,724,243 |
| 26 | Lucentis | $1,917,919,037 |
| 27 | Namenda | $1,871,956,353 |
| 28 | Vyvanse | $1,848,814,801 |
| 29 | Zetia | $1,826,260,072 |
| 30 | Levemir | $1,775,037,064 |
| 31 | Symbicort | $1,733,830,589 |
| 32 | Sovaldi | $1,724,867,241 |
| 33 | Novolog Flexpen | $1,482,659,229 |
| 34 | Novolog | $1,409,680,368 |
| 35 | Tecfidera | $1,394,704,148 |
| 36 | Suboxone | $1,388,805,102 |
| 37 | Humalog | $1,310,236,982 |
| 38 | Xarelto | $1,263,697,546 |
| 39 | Seroquel XR | $1,251,615,894 |
| 40 | Viagra | $1,235,125,299 |
| 41 | Alimta | $1,205,717,422 |
| 42 | Victoza 3-Pak | $1,186,784,355 |
| 43 | Avonex | $1,184,476,004 |
| 44 | Nasonex | $1,180,165,756 |
| 45 | Cialis | $1,170,843,904 |
| 46 | Gilenya | $1,097,409,827 |
| 47 | Stelara | $1,083,660,282 |
| 48 | Flovent HFA | $1,078,422,967 |
| 49 | Prezista | $1,046,464,870 |
| 50 | Procrit | $1,037,298,436 |
| 51 | Isentress | $1,037,220,122 |
| 52 | Janumet | $1,028,179,032 |
| 53 | Renvela | $1,023,751,529 |
| 54 | Humalog Kwikpen | $1,003,100,788 |
| 55 | Orencia | $990,449,529 |
| 56 | Dexilant | $967,408,551 |
| 57 | Vesicare | $967,408,277 |
| 58 | Neupogen | $944,389,150 |
| 59 | Reyataz | $935,417,307 |
| 60 | Lunesta | $927,689,337 |
| 61 | Synthroid | $899,215,664 |
| 62 | Pradaxa | $862,604,444 |
| 63 | Zytiga | $861,683,197 |
| 64 | Benicar | $860,761,655 |
| 65 | Xolair | $859,052,353 |
| 66 | Avonex Pen | $849,256,894 |
| 67 | Vytorin | $846,602,646 |
| 68 | Invega Sustenna | $831,061,694 |
| 69 | Sensipar | $824,871,721 |
| 70 | Xgeva | $822,603,435 |
| 71 | Prevnar 13 | $821,372,081 |
| 72 | Evista | $815,315,970 |
| 73 | Aranesp | $814,017,366 |
| 74 | Betaseron | $792,093,855 |
| 75 | Stribild | $785,645,319 |
| 76 | Combivent Respimat | $768,925,543 |
| 77 | Xeloda | $761,832,629 |
| 78 | Afinitor | $761,796,538 |
| 79 | Ventolin HFA | $761,324,992 |
| 80 | Synagis | $755,220,544 |
| 81 | Zyvox | $732,206,096 |
| 82 | Bystolic | $719,917,435 |
| 83 | Sandostatin LAR | $708,264,105 |
| 84 | Complera | $696,270,123 |
| 85 | Benicar HCT | $692,128,910 |
| 86 | Treanda | $691,670,874 |
| 87 | Gardasil | $683,558,728 |
| 88 | Zostavax | $679,653,129 |
| 89 | Pristiq | $660,397,547 |
| 90 | Erbitux | $660,368,777 |
| 91 | Focalin XR | $647,720,027 |
| 92 | Tarceva | $646,108,218 |
| 93 | Cubicin | $643,649,546 |
| 94 | Strattera | $640,562,124 |
| 95 | Latuda | $639,903,393 |
| 96 | Velcade | $624,619,639 |
| 97 | Viread | $606,046,798 |
| 98 | Welchol | $603,644,260 |
| 99 | Nuvaring | $600,191,343 |
| 100 | Sprycel | $599,882,414 |
| Source: IMS National Prescription Audit, IMS Health. | ||
Scientific Case Review
Would you like to understand whether current clinical programs, recent research developments, or emerging approaches may be relevant to your individual situation?
Send your question to our scientific team. The NBScience head office in the United Kingdom coordinates inquiries across international network of medical centres, scientists, and specialised consultants.
- Review of the information you provide
- Relevant research and clinical program information
- A clear response focused on your situation
What happens next?
Send your question, receive a focused scientific review, and get a clear response about research and clinical programs relevant to your situation.
Your scientific review will be prepared by Dr. Helen Melnik,PhD , who has more than 25 years of experience in stem cell research and international clinical programs.
No obligation. Your question will be reviewed confidentially.
Educational and research information only. This service does not constitute medical advice, diagnosis, prescription, or a personalized treatment recommendation.
